Cynthia L Gay, Ronald J Bosch, Ashley McKhann, Raymond Cha, Gene D Morse, Chanelle L Wimbish, Danielle M Campbell, Kendall F Moseley, Steven Hendrickx, Michael Messer, Constance A Benson, Edgar T Overton, Anne Paccaly, Vladimir Jankovic, Elizabeth Miller, Randall Tressler, Jonathan Z Li, Daniel R Kuritzkes, Bernard J C Macatangay, Joseph J Eron, W David Hardy
BACKGROUND: T cells in people with human immunodeficiency virus (HIV) demonstrate an exhausted phenotype, and HIV-specific CD4+ T cells expressing programmed cell death 1 (PD-1) are enriched for latent HIV, making antibody to PD-1 a potential strategy to target the latent reservoir. METHODS: This was a phase 1/2, randomized (4:1), double-blind, placebo-controlled study in adults with suppressed HIV on antiretroviral therapy with CD4+ counts ≥350 cells/μL who received 2 infusions of cemiplimab versus placebo...
March 2024: Open Forum Infectious Diseases